Review

colon carcinoma cell line ct26 (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC colon carcinoma cell line ct26

( A-D ) Luc–encoding RNA formulated as RNA-LPX was administered i.v. to non-tumor bearing (A, B; n=3) or <t>CT26</t> metastases-bearing (C, D) BALB/c mice (n=3-9). ( A ) BLI of total body, ( B ) normalized organ signal from explanted organs. Data were analyzed by ordinary one-way ANOVA and Tukey’s test for multiple comparisons. ( C ) Kinetics of BLI of the lung signal in metastases-bearing mice, significance was determined by mixed-effects analysis with Geisser-Greenhouse correction and Tukey’s test for multiple comparisons. ( D ) Luc RNA, luc protein and CD31 (PECAM-1) were detected via RNAscope and immunohistochemistry on consecutive sections 1, 6 or 24 hours post injection, scale bar: 100 µm, tumor tissue is indicated with dashed line. ( E ) Cytokine quantification in lung after the indicated time points. ( F ) Cytokine fold increase in lung normalized to spleen at 6 hours after injection. ( G ) FDG positron emission tomography (PET) imaging 24 h after cytokine RNA mix injection into naïve mice, ( H ) ex vivo measurement of FDG uptake. Significance was determined using a two-tailed t-test for unpaired samples.

Colon Carcinoma Cell Line Ct26, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 3089 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ct26+colon+carcinoma+cells/bio_rxiv__64898__2026__05__06__723126-200-0-8?v=ATCC
Average 99 stars, based on 3089 article reviews

colon carcinoma cell line ct26 - by Bioz Stars, 2026-07

99/100 stars

Images

1) Product Images from "Lung-targeted cytokine-coding RNA-lipoplexes induce T and NK cell-mediated anti-tumor immune response"

Article Title: Lung-targeted cytokine-coding RNA-lipoplexes induce T and NK cell-mediated anti-tumor immune response

Journal: bioRxiv

doi: 10.64898/2026.05.06.723126

( A-D ) Luc–encoding RNA formulated as RNA-LPX was administered i.v. to non-tumor bearing (A, B; n=3) or CT26 metastases-bearing (C, D) BALB/c mice (n=3-9). ( A ) BLI of total body, ( B ) normalized organ signal from explanted organs. Data were analyzed by ordinary one-way ANOVA and Tukey’s test for multiple comparisons. ( C ) Kinetics of BLI of the lung signal in metastases-bearing mice, significance was determined by mixed-effects analysis with Geisser-Greenhouse correction and Tukey’s test for multiple comparisons. ( D ) Luc RNA, luc protein and CD31 (PECAM-1) were detected via RNAscope and immunohistochemistry on consecutive sections 1, 6 or 24 hours post injection, scale bar: 100 µm, tumor tissue is indicated with dashed line. ( E ) Cytokine quantification in lung after the indicated time points. ( F ) Cytokine fold increase in lung normalized to spleen at 6 hours after injection. ( G ) FDG positron emission tomography (PET) imaging 24 h after cytokine RNA mix injection into naïve mice, ( H ) ex vivo measurement of FDG uptake. Significance was determined using a two-tailed t-test for unpaired samples.

Figure Legend Snippet: ( A-D ) Luc–encoding RNA formulated as RNA-LPX was administered i.v. to non-tumor bearing (A, B; n=3) or CT26 metastases-bearing (C, D) BALB/c mice (n=3-9). ( A ) BLI of total body, ( B ) normalized organ signal from explanted organs. Data were analyzed by ordinary one-way ANOVA and Tukey’s test for multiple comparisons. ( C ) Kinetics of BLI of the lung signal in metastases-bearing mice, significance was determined by mixed-effects analysis with Geisser-Greenhouse correction and Tukey’s test for multiple comparisons. ( D ) Luc RNA, luc protein and CD31 (PECAM-1) were detected via RNAscope and immunohistochemistry on consecutive sections 1, 6 or 24 hours post injection, scale bar: 100 µm, tumor tissue is indicated with dashed line. ( E ) Cytokine quantification in lung after the indicated time points. ( F ) Cytokine fold increase in lung normalized to spleen at 6 hours after injection. ( G ) FDG positron emission tomography (PET) imaging 24 h after cytokine RNA mix injection into naïve mice, ( H ) ex vivo measurement of FDG uptake. Significance was determined using a two-tailed t-test for unpaired samples.

Techniques Used: RNAscope, Immunohistochemistry, Injection, Positron Emission Tomography, Imaging, Ex Vivo, Two Tailed Test

( A ) Experimental design: BALB/c mice (n=15 per group) were injected i.v. with CT26 tumor cells; subsequently, cytokine RNA mix or irrelevant RNA was administered i.v. as RNA-LPX twice per week for a total of 8 injections from d3 to d27. Survivor mice from the cytokine RNA mix-treated group (n=5) compared to naïve BALB/c mice (n=10) were re-challenged with CT26 tumor cells. ( B ) Survival after the initial i.v. CT26 tumor cell inoculation. ( C ) Survival after re-challenge. Significance was determined via Mantel-Cox logrank. ( D-F ) BALB/c mice (n=5 per group) were injected i.v. with CT26 tumor cells, RNA-LPX was administered i.v. at d3, d6 and d10 p.t.i., mice were sacrificed at d11, lungs were collected and analyzed via flow cytometry. Significance for pairwise comparisons was determined by unpaired two-tailed t-test. Flow cytometric analysis of ( D ) tumor burden, ( E ) CD8 + T and NK cells and ( F ) CD4 + Foxp3 + CD25 + T reg . ( G ) Functional analysis: after tumor cell inoculation, mice were treated with RNA-LPX at d3, d6, d10 and d13 p.t.i., mice were sacrificed at d14 for an ex vivo stimulation assay with PMA/Ionomycin ( H ) qRT-PCR was done to determine fold-change expression of cytokine RNA mix-treated normalized to irrelevant RNA LPX-treated lung samples (n=5 per group indicated in rows) for the indicated cytokines and chemokines.

Figure Legend Snippet: ( A ) Experimental design: BALB/c mice (n=15 per group) were injected i.v. with CT26 tumor cells; subsequently, cytokine RNA mix or irrelevant RNA was administered i.v. as RNA-LPX twice per week for a total of 8 injections from d3 to d27. Survivor mice from the cytokine RNA mix-treated group (n=5) compared to naïve BALB/c mice (n=10) were re-challenged with CT26 tumor cells. ( B ) Survival after the initial i.v. CT26 tumor cell inoculation. ( C ) Survival after re-challenge. Significance was determined via Mantel-Cox logrank. ( D-F ) BALB/c mice (n=5 per group) were injected i.v. with CT26 tumor cells, RNA-LPX was administered i.v. at d3, d6 and d10 p.t.i., mice were sacrificed at d11, lungs were collected and analyzed via flow cytometry. Significance for pairwise comparisons was determined by unpaired two-tailed t-test. Flow cytometric analysis of ( D ) tumor burden, ( E ) CD8 + T and NK cells and ( F ) CD4 + Foxp3 + CD25 + T reg . ( G ) Functional analysis: after tumor cell inoculation, mice were treated with RNA-LPX at d3, d6, d10 and d13 p.t.i., mice were sacrificed at d14 for an ex vivo stimulation assay with PMA/Ionomycin ( H ) qRT-PCR was done to determine fold-change expression of cytokine RNA mix-treated normalized to irrelevant RNA LPX-treated lung samples (n=5 per group indicated in rows) for the indicated cytokines and chemokines.

Techniques Used: Injection, Flow Cytometry, Two Tailed Test, Functional Assay, Ex Vivo, Quantitative RT-PCR, Expressing

Experimental design: BALB/c mice (n=5 per group) were injected i.v. with CT26 tumor cells; cytokine RNA mix or irrelevant RNA was administered i.v. at d3, d6 and d10 post tumor cell injection, mice were sacrificed at d11, lungs were collected and pooled at same ratios before sorting of CD45 + cells. CD45 + cells were subjected to scRNAseq. ( A,B ) Uniform manifold approximation and projection (UMAP) of 22 assigned clusters ( A ) and cell type frequencies ( B ) of CD45 + cells isolated from the lungs of cytokine RNA mix-treated versus irrelevant RNA-treated mice. ( C ) Effector function visualized as bubble plot. ( D ) Selected differentially expressed genes in cytokine RNA mix-treated versus irrelevant RNA-treated samples are shown as average log2 fold change. Note only significantly expressed values (p ≤ 0.05) are shown in colouring (blue = downregulated, red = upregulated), non-significant values are set to “0”/white.

Figure Legend Snippet: Experimental design: BALB/c mice (n=5 per group) were injected i.v. with CT26 tumor cells; cytokine RNA mix or irrelevant RNA was administered i.v. at d3, d6 and d10 post tumor cell injection, mice were sacrificed at d11, lungs were collected and pooled at same ratios before sorting of CD45 + cells. CD45 + cells were subjected to scRNAseq. ( A,B ) Uniform manifold approximation and projection (UMAP) of 22 assigned clusters ( A ) and cell type frequencies ( B ) of CD45 + cells isolated from the lungs of cytokine RNA mix-treated versus irrelevant RNA-treated mice. ( C ) Effector function visualized as bubble plot. ( D ) Selected differentially expressed genes in cytokine RNA mix-treated versus irrelevant RNA-treated samples are shown as average log2 fold change. Note only significantly expressed values (p ≤ 0.05) are shown in colouring (blue = downregulated, red = upregulated), non-significant values are set to “0”/white.

Techniques Used: Injection, Isolation

( A ) Experimental design for ( B-C; CT26 tumor model) and ( E; CT26 B2M k.o. tumor model); n=15 BALB/c mice per group. Depletion or blocking antibody treatment was started 2 days prior to RNA-LPX treatment to ensure depletion before treatment start. ( B, C ) Survival according to termination criteria. ( D ) Experimental design and survival in CT26B2M k.o. or CT26gp70 k.o. tumor cells i.v. tumor model, n=15 mice per group. ( E ) BALB/c mice injected i.v. with CT26B2M k.o and depletion/neutralization antibodies were applied as shown in ( A ). Note that data in ( E ) were generated within the same experiment, irrelevant RNA + isotype mix as well as cytokine mix RNA + isotype mix refers to the same groups in all 3 plots. Survival was analyzed via Mantel-Cox logrank test. For ( B ) and ( C ), groups 1 and 2 were furthermore compared via logrank test with emphasis on early and late differences, ( B ) ## Logrank test with emphasis on late differences ((rho=0, lambda=1): group 1 vs 2: p=0,00235; ( C ) # Logrank test with emphasis on early differences (rho=1, lambda=0): group 1 vs 2: p=0,0378.

Figure Legend Snippet: ( A ) Experimental design for ( B-C; CT26 tumor model) and ( E; CT26 B2M k.o. tumor model); n=15 BALB/c mice per group. Depletion or blocking antibody treatment was started 2 days prior to RNA-LPX treatment to ensure depletion before treatment start. ( B, C ) Survival according to termination criteria. ( D ) Experimental design and survival in CT26B2M k.o. or CT26gp70 k.o. tumor cells i.v. tumor model, n=15 mice per group. ( E ) BALB/c mice injected i.v. with CT26B2M k.o and depletion/neutralization antibodies were applied as shown in ( A ). Note that data in ( E ) were generated within the same experiment, irrelevant RNA + isotype mix as well as cytokine mix RNA + isotype mix refers to the same groups in all 3 plots. Survival was analyzed via Mantel-Cox logrank test. For ( B ) and ( C ), groups 1 and 2 were furthermore compared via logrank test with emphasis on early and late differences, ( B ) ## Logrank test with emphasis on late differences ((rho=0, lambda=1): group 1 vs 2: p=0,00235; ( C ) # Logrank test with emphasis on early differences (rho=1, lambda=0): group 1 vs 2: p=0,0378.

Techniques Used: Blocking Assay, Injection, Neutralization, Generated

Image Search Results

Journal: bioRxiv

Article Title: Lung-targeted cytokine-coding RNA-lipoplexes induce T and NK cell-mediated anti-tumor immune response

doi: 10.64898/2026.05.06.723126

Figure Lengend Snippet: ( A-D ) Luc–encoding RNA formulated as RNA-LPX was administered i.v. to non-tumor bearing (A, B; n=3) or CT26 metastases-bearing (C, D) BALB/c mice (n=3-9). ( A ) BLI of total body, ( B ) normalized organ signal from explanted organs. Data were analyzed by ordinary one-way ANOVA and Tukey’s test for multiple comparisons. ( C ) Kinetics of BLI of the lung signal in metastases-bearing mice, significance was determined by mixed-effects analysis with Geisser-Greenhouse correction and Tukey’s test for multiple comparisons. ( D ) Luc RNA, luc protein and CD31 (PECAM-1) were detected via RNAscope and immunohistochemistry on consecutive sections 1, 6 or 24 hours post injection, scale bar: 100 µm, tumor tissue is indicated with dashed line. ( E ) Cytokine quantification in lung after the indicated time points. ( F ) Cytokine fold increase in lung normalized to spleen at 6 hours after injection. ( G ) FDG positron emission tomography (PET) imaging 24 h after cytokine RNA mix injection into naïve mice, ( H ) ex vivo measurement of FDG uptake. Significance was determined using a two-tailed t-test for unpaired samples.

Article Snippet: Colon Carcinoma cell line CT26 was purchased from ATCC (CT26: CRL-2638, lot no. 58494154, female).

Techniques: RNAscope, Immunohistochemistry, Injection, Positron Emission Tomography, Imaging, Ex Vivo, Two Tailed Test

Journal: bioRxiv

Article Title: Lung-targeted cytokine-coding RNA-lipoplexes induce T and NK cell-mediated anti-tumor immune response

doi: 10.64898/2026.05.06.723126

Figure Lengend Snippet: ( A ) Experimental design: BALB/c mice (n=15 per group) were injected i.v. with CT26 tumor cells; subsequently, cytokine RNA mix or irrelevant RNA was administered i.v. as RNA-LPX twice per week for a total of 8 injections from d3 to d27. Survivor mice from the cytokine RNA mix-treated group (n=5) compared to naïve BALB/c mice (n=10) were re-challenged with CT26 tumor cells. ( B ) Survival after the initial i.v. CT26 tumor cell inoculation. ( C ) Survival after re-challenge. Significance was determined via Mantel-Cox logrank. ( D-F ) BALB/c mice (n=5 per group) were injected i.v. with CT26 tumor cells, RNA-LPX was administered i.v. at d3, d6 and d10 p.t.i., mice were sacrificed at d11, lungs were collected and analyzed via flow cytometry. Significance for pairwise comparisons was determined by unpaired two-tailed t-test. Flow cytometric analysis of ( D ) tumor burden, ( E ) CD8 + T and NK cells and ( F ) CD4 + Foxp3 + CD25 + T reg . ( G ) Functional analysis: after tumor cell inoculation, mice were treated with RNA-LPX at d3, d6, d10 and d13 p.t.i., mice were sacrificed at d14 for an ex vivo stimulation assay with PMA/Ionomycin ( H ) qRT-PCR was done to determine fold-change expression of cytokine RNA mix-treated normalized to irrelevant RNA LPX-treated lung samples (n=5 per group indicated in rows) for the indicated cytokines and chemokines.

Article Snippet: Colon Carcinoma cell line CT26 was purchased from ATCC (CT26: CRL-2638, lot no. 58494154, female).

Techniques: Injection, Flow Cytometry, Two Tailed Test, Functional Assay, Ex Vivo, Quantitative RT-PCR, Expressing

Journal: bioRxiv

Article Title: Lung-targeted cytokine-coding RNA-lipoplexes induce T and NK cell-mediated anti-tumor immune response

doi: 10.64898/2026.05.06.723126

Figure Lengend Snippet: Experimental design: BALB/c mice (n=5 per group) were injected i.v. with CT26 tumor cells; cytokine RNA mix or irrelevant RNA was administered i.v. at d3, d6 and d10 post tumor cell injection, mice were sacrificed at d11, lungs were collected and pooled at same ratios before sorting of CD45 + cells. CD45 + cells were subjected to scRNAseq. ( A,B ) Uniform manifold approximation and projection (UMAP) of 22 assigned clusters ( A ) and cell type frequencies ( B ) of CD45 + cells isolated from the lungs of cytokine RNA mix-treated versus irrelevant RNA-treated mice. ( C ) Effector function visualized as bubble plot. ( D ) Selected differentially expressed genes in cytokine RNA mix-treated versus irrelevant RNA-treated samples are shown as average log2 fold change. Note only significantly expressed values (p ≤ 0.05) are shown in colouring (blue = downregulated, red = upregulated), non-significant values are set to “0”/white.

Article Snippet: Colon Carcinoma cell line CT26 was purchased from ATCC (CT26: CRL-2638, lot no. 58494154, female).

Techniques: Injection, Isolation

Journal: bioRxiv

Article Title: Lung-targeted cytokine-coding RNA-lipoplexes induce T and NK cell-mediated anti-tumor immune response

doi: 10.64898/2026.05.06.723126

Figure Lengend Snippet: ( A ) Experimental design for ( B-C; CT26 tumor model) and ( E; CT26 B2M k.o. tumor model); n=15 BALB/c mice per group. Depletion or blocking antibody treatment was started 2 days prior to RNA-LPX treatment to ensure depletion before treatment start. ( B, C ) Survival according to termination criteria. ( D ) Experimental design and survival in CT26B2M k.o. or CT26gp70 k.o. tumor cells i.v. tumor model, n=15 mice per group. ( E ) BALB/c mice injected i.v. with CT26B2M k.o and depletion/neutralization antibodies were applied as shown in ( A ). Note that data in ( E ) were generated within the same experiment, irrelevant RNA + isotype mix as well as cytokine mix RNA + isotype mix refers to the same groups in all 3 plots. Survival was analyzed via Mantel-Cox logrank test. For ( B ) and ( C ), groups 1 and 2 were furthermore compared via logrank test with emphasis on early and late differences, ( B ) ## Logrank test with emphasis on late differences ((rho=0, lambda=1): group 1 vs 2: p=0,00235; ( C ) # Logrank test with emphasis on early differences (rho=1, lambda=0): group 1 vs 2: p=0,0378.

Article Snippet: Colon Carcinoma cell line CT26 was purchased from ATCC (CT26: CRL-2638, lot no. 58494154, female).

Techniques: Blocking Assay, Injection, Neutralization, Generated

TAMpep-IP suppresses tumor growth in the colon cancer model. (A) BALB/c mice were subcutaneously inoculated with CT26 colon carcinoma cells (3 × 10 5 cells per mouse). Starting on day 7 post-inoculation, TAMpep-IP (400 nmol/kg) was administered subcutaneously every three days for a total of seven doses. (B) Representative images of tumors excised at the experimental endpoint (day 25) showed visibly reduced tumor size in the TAMpep-IP–treated group compared to control. (C) Tumor volumes were measured every 3 days following tumor implantation. Mice treated with TAMpep-IP exhibited significantly reduced tumor growth relative to the control group (control: n = 6; TAMpep-IP: n = 6). (D) Tumor proliferation was evaluated by immunohistochemical staining of Ki-67 in tumor sections. Quantitative analysis showed a significantly lower proportion of Ki-67 + proliferating cells in TAMpep-IP–treated tumors. Representative immunohistochemistry images were acquired at ×100 magnification. Scale bar = 1000 μm. All data are presented as mean ± SEM. *p<0.05, ***p<0.001.

Journal: Frontiers in Immunology

Article Title: STAT6 inhibition of M2 macrophages suppresses tumor growth by modulating the tumor microenvironment in colon cancer model

doi: 10.3389/fimmu.2026.1733991

Figure Lengend Snippet: TAMpep-IP suppresses tumor growth in the colon cancer model. (A) BALB/c mice were subcutaneously inoculated with CT26 colon carcinoma cells (3 × 10 5 cells per mouse). Starting on day 7 post-inoculation, TAMpep-IP (400 nmol/kg) was administered subcutaneously every three days for a total of seven doses. (B) Representative images of tumors excised at the experimental endpoint (day 25) showed visibly reduced tumor size in the TAMpep-IP–treated group compared to control. (C) Tumor volumes were measured every 3 days following tumor implantation. Mice treated with TAMpep-IP exhibited significantly reduced tumor growth relative to the control group (control: n = 6; TAMpep-IP: n = 6). (D) Tumor proliferation was evaluated by immunohistochemical staining of Ki-67 in tumor sections. Quantitative analysis showed a significantly lower proportion of Ki-67 + proliferating cells in TAMpep-IP–treated tumors. Representative immunohistochemistry images were acquired at ×100 magnification. Scale bar = 1000 μm. All data are presented as mean ± SEM. *p<0.05, ***p<0.001.

Article Snippet: The murine colon carcinoma cell line CT26 (KCLB 80009; Korean Cell Line Bank, Seoul, Korea) was cultured in Dulbecco’s modified Eagle’s medium (DMEM) (D5671; Welgene, Gyeongsangbuk, Korea) supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin, and 1% penicillin–streptomycin.

Techniques: Control, Tumor Implantation, Immunohistochemical staining, Staining, Immunohistochemistry

TAMpep-IP reduces M2 macrophages in tumor tissues of colon cancer model. (A) Tumor-infiltrating immune cells were isolated from CT26 tumors in control and TAMpep-IP–treated mice. Flow cytometry was used to identify CD206 + F4/80 + macrophages within the CD45 + CD11b + population. TAMpep-IP significantly decreased the proportion of M2-like tumor-associated macrophages. (B) Quantitative RT-PCR analysis of tumor tissues revealed that TGF-β mRNA expression, a key M2-associated cytokine, was significantly reduced in TAMpep-IP–treated tumors compared to controls. (C) Western blot analysis of tumor showed a marked decrease in CD206 protein levels following TAMpep-IP, indicating effective suppression of M2 macrophage markers. (D) CD206 + macrophages were further visualized by immunohistochemical staining of tumor sections. ImageJ-based quantification confirmed a significant reduction in CD206 + area in TAMpep-IP–treated tumors. Representative immunohistochemistry images were acquired at ×100 magnification. Scale bar = 1000 μm. All data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001.

Journal: Frontiers in Immunology

Article Title: STAT6 inhibition of M2 macrophages suppresses tumor growth by modulating the tumor microenvironment in colon cancer model

doi: 10.3389/fimmu.2026.1733991

Figure Lengend Snippet: TAMpep-IP reduces M2 macrophages in tumor tissues of colon cancer model. (A) Tumor-infiltrating immune cells were isolated from CT26 tumors in control and TAMpep-IP–treated mice. Flow cytometry was used to identify CD206 + F4/80 + macrophages within the CD45 + CD11b + population. TAMpep-IP significantly decreased the proportion of M2-like tumor-associated macrophages. (B) Quantitative RT-PCR analysis of tumor tissues revealed that TGF-β mRNA expression, a key M2-associated cytokine, was significantly reduced in TAMpep-IP–treated tumors compared to controls. (C) Western blot analysis of tumor showed a marked decrease in CD206 protein levels following TAMpep-IP, indicating effective suppression of M2 macrophage markers. (D) CD206 + macrophages were further visualized by immunohistochemical staining of tumor sections. ImageJ-based quantification confirmed a significant reduction in CD206 + area in TAMpep-IP–treated tumors. Representative immunohistochemistry images were acquired at ×100 magnification. Scale bar = 1000 μm. All data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001.

Techniques: Isolation, Control, Flow Cytometry, Quantitative RT-PCR, Expressing, Western Blot, Immunohistochemical staining, Staining, Immunohistochemistry

TAMpep-IP enhances inflammatory cytokine expression and activated CD8 + T cells in tumor tissues of colon cancer model. (A) Flow cytometry was used to evaluate CD8 + T cell function in CT26 tumor tissues from control and TAMpep-IP-treated mice. TAMpep-IP significantly increased the proportion of activated Granzyme B + CD8 + T cells, while reducing the frequency of exhausted Tim-3 + CD8 + T cells, indicating enhanced cytotoxic T cell activity. (B, C) Confocal immunofluorescence analysis was performed on tumor sections stained with DAPI (nuclei), anti-CD8 (green), anti-Granzyme B (red), and anti-PD-1 (red). Activated CD8 + T cells were identified by co-localization of CD8 and Granzyme B, whereas exhausted CD8 + T cells were identified by co-localization of CD8 and PD-1. Quantification revealed a significant increase in intertumoral CD8 + Granzyme B + T cells and a concomitant decrease in CD8 + PD-1 + exhausted T cells following TAMpep-IP. Representative confocal images were acquired using a 40× objective lens. Scale bar = 20 μm. (D) Quantitative RT-PCR analysis of CT26 tumor tissues showed significantly elevated mRNA levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-12 in TAMpep-IP–treated mice compared to controls, indicating induction of a pro-inflammatory tumor microenvironment. All data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p < 0.0001.

Journal: Frontiers in Immunology

Article Title: STAT6 inhibition of M2 macrophages suppresses tumor growth by modulating the tumor microenvironment in colon cancer model

doi: 10.3389/fimmu.2026.1733991

Figure Lengend Snippet: TAMpep-IP enhances inflammatory cytokine expression and activated CD8 + T cells in tumor tissues of colon cancer model. (A) Flow cytometry was used to evaluate CD8 + T cell function in CT26 tumor tissues from control and TAMpep-IP-treated mice. TAMpep-IP significantly increased the proportion of activated Granzyme B + CD8 + T cells, while reducing the frequency of exhausted Tim-3 + CD8 + T cells, indicating enhanced cytotoxic T cell activity. (B, C) Confocal immunofluorescence analysis was performed on tumor sections stained with DAPI (nuclei), anti-CD8 (green), anti-Granzyme B (red), and anti-PD-1 (red). Activated CD8 + T cells were identified by co-localization of CD8 and Granzyme B, whereas exhausted CD8 + T cells were identified by co-localization of CD8 and PD-1. Quantification revealed a significant increase in intertumoral CD8 + Granzyme B + T cells and a concomitant decrease in CD8 + PD-1 + exhausted T cells following TAMpep-IP. Representative confocal images were acquired using a 40× objective lens. Scale bar = 20 μm. (D) Quantitative RT-PCR analysis of CT26 tumor tissues showed significantly elevated mRNA levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-12 in TAMpep-IP–treated mice compared to controls, indicating induction of a pro-inflammatory tumor microenvironment. All data are presented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p < 0.0001.

Techniques: Expressing, Flow Cytometry, Cell Function Assay, Control, Activity Assay, Immunofluorescence, Staining, Quantitative RT-PCR

Cytotoxic and anti-cancer activity of the N1: (A) dose-dependent inhibition of cell proliferation in murine colon carcinoma cell lines (CT26 and MC-38) and human colorectal cancer cell line (HCT-15) upon treatment with increasing concentrations of N1, determined by MTT assay; (B) cell viability of normal murine fibroblast cells (NIH-3T3) following treatment with N1 at indicated concentrations, demonstrating minimal cytotoxicity; (C–E) dose–response curves showing percentage growth inhibition and corresponding IC 50 values for CT26 (C), MC-38 (D), and HCT-15 (E) cells. IC 50 values are calculated by nonlinear regression analysis using GraphPad Prism. Data are expressed as mean ± SD ( n = 3).

Journal: RSC Advances

Article Title: Exploring an azo-uracil based nickel( ii ) complex for anticancer and phosphatase like activities

doi: 10.1039/d6ra01587e

Figure Lengend Snippet: Cytotoxic and anti-cancer activity of the N1: (A) dose-dependent inhibition of cell proliferation in murine colon carcinoma cell lines (CT26 and MC-38) and human colorectal cancer cell line (HCT-15) upon treatment with increasing concentrations of N1, determined by MTT assay; (B) cell viability of normal murine fibroblast cells (NIH-3T3) following treatment with N1 at indicated concentrations, demonstrating minimal cytotoxicity; (C–E) dose–response curves showing percentage growth inhibition and corresponding IC 50 values for CT26 (C), MC-38 (D), and HCT-15 (E) cells. IC 50 values are calculated by nonlinear regression analysis using GraphPad Prism. Data are expressed as mean ± SD ( n = 3).

Article Snippet: Murine colon carcinoma cell lines CT26 and MC-38, human colorectal carcinoma cell line HCT-15, and normal murine fibroblast cell line NIH-3T3 were procured from the ATCC, USA.

Techniques: Activity Assay, Inhibition, MTT Assay

N1 induced apoptosis in colon cancer cells: (A) representative bright-field and fluorescence micrographs of CT26 cells treated with N1 (0.04 and 0.08 µg mL −1 ) for 12 h and stained with Annexin V-FITC (green) and propidium iodide (PI, red); merged images indicate apoptotic cell populations; (B–E) flow cytometric dot plots of Annexin V-FITC/PI staining showing viable (Q4, Annexin V − /PI − ), early apoptotic (Q3, Annexin V + /PI − ), late apoptotic (Q2, Annexin V + /PI + ), and necrotic (Q1, Annexin V − /PI + ) cell populations in untreated control (B), doxorubicin-treated positive control (0.25 µM) (C), and N1-treated cells at 0.04 µg mL −1 (D) and 0.08 µg mL −1 (E); (F) overlay histogram showing fluorescence intensity shifts in the FITC channel for control, doxorubicin, and N1-treated cells; (G) quantitative analysis of percentage dead/apoptotic cells under different treatment conditions (mean ± SD, n = 3; *** p < 0.001 vs. control).

Journal: RSC Advances

Article Title: Exploring an azo-uracil based nickel( ii ) complex for anticancer and phosphatase like activities

doi: 10.1039/d6ra01587e

Figure Lengend Snippet: N1 induced apoptosis in colon cancer cells: (A) representative bright-field and fluorescence micrographs of CT26 cells treated with N1 (0.04 and 0.08 µg mL −1 ) for 12 h and stained with Annexin V-FITC (green) and propidium iodide (PI, red); merged images indicate apoptotic cell populations; (B–E) flow cytometric dot plots of Annexin V-FITC/PI staining showing viable (Q4, Annexin V − /PI − ), early apoptotic (Q3, Annexin V + /PI − ), late apoptotic (Q2, Annexin V + /PI + ), and necrotic (Q1, Annexin V − /PI + ) cell populations in untreated control (B), doxorubicin-treated positive control (0.25 µM) (C), and N1-treated cells at 0.04 µg mL −1 (D) and 0.08 µg mL −1 (E); (F) overlay histogram showing fluorescence intensity shifts in the FITC channel for control, doxorubicin, and N1-treated cells; (G) quantitative analysis of percentage dead/apoptotic cells under different treatment conditions (mean ± SD, n = 3; *** p < 0.001 vs. control).

Article Snippet: Murine colon carcinoma cell lines CT26 and MC-38, human colorectal carcinoma cell line HCT-15, and normal murine fibroblast cell line NIH-3T3 were procured from the ATCC, USA.

Techniques: Fluorescence, Staining, Control, Positive Control

Mechanistic insights into N1-induced apoptosis: caspase dependence, ROS generation, and mitochondrial perturbation: (A) representative flow cytometric dot plots of Annexin V-FITC/PI staining in CT26 cells treated with N1 (0.04 and 0.08 µg mL −1 ) for 12 h, showing viable (Annexin V − /PI − ), early apoptotic (Annexin V + /PI − ), late apoptotic (Annexin V + /PI + ), and necrotic (Annexin V − /PI + ) populations; (B) effect of pan-caspase inhibitor Z-VAD-FMK (20 µM, 1 h pre-treatment) on N1-induced apoptosis, showing reduced Annexin V-positive cell populations; (C) flow cytometric histograms of intracellular ROS levels measured using CellROX Green (total ROS) and MitoSOX Red (mitochondrial superoxide) in untreated, doxorubicin-treated (0.25 µM), and N1-treated cells (0.04 and 0.08 µg mL −1 ), indicating predominant induction of total ROS; (D) assessment of mitochondrial membrane potential (Δ Ψ m) using JC-1 staining, showing changes in red (JC-1 aggregates) and green (JC-1 monomers) fluorescence in control, N1-treated, and doxorubicin-treated cells, indicative of moderate mitochondrial depolarization. All experiments were performed in CT26 cells and analysed by flow cytometry. Data shown are representative of three independent experiments.

Journal: RSC Advances

Article Title: Exploring an azo-uracil based nickel( ii ) complex for anticancer and phosphatase like activities

doi: 10.1039/d6ra01587e

Figure Lengend Snippet: Mechanistic insights into N1-induced apoptosis: caspase dependence, ROS generation, and mitochondrial perturbation: (A) representative flow cytometric dot plots of Annexin V-FITC/PI staining in CT26 cells treated with N1 (0.04 and 0.08 µg mL −1 ) for 12 h, showing viable (Annexin V − /PI − ), early apoptotic (Annexin V + /PI − ), late apoptotic (Annexin V + /PI + ), and necrotic (Annexin V − /PI + ) populations; (B) effect of pan-caspase inhibitor Z-VAD-FMK (20 µM, 1 h pre-treatment) on N1-induced apoptosis, showing reduced Annexin V-positive cell populations; (C) flow cytometric histograms of intracellular ROS levels measured using CellROX Green (total ROS) and MitoSOX Red (mitochondrial superoxide) in untreated, doxorubicin-treated (0.25 µM), and N1-treated cells (0.04 and 0.08 µg mL −1 ), indicating predominant induction of total ROS; (D) assessment of mitochondrial membrane potential (Δ Ψ m) using JC-1 staining, showing changes in red (JC-1 aggregates) and green (JC-1 monomers) fluorescence in control, N1-treated, and doxorubicin-treated cells, indicative of moderate mitochondrial depolarization. All experiments were performed in CT26 cells and analysed by flow cytometry. Data shown are representative of three independent experiments.

Article Snippet: Murine colon carcinoma cell lines CT26 and MC-38, human colorectal carcinoma cell line HCT-15, and normal murine fibroblast cell line NIH-3T3 were procured from the ATCC, USA.

Techniques: Staining, Membrane, Fluorescence, Control, Flow Cytometry

Effect of ROS scavenging and phosphatase inhibition on N1-induced cytotoxicity: (A) percentage cytotoxicity in CT26 cells treated with N1 (0.04 and 0.08 µg mL −1 ) in the presence or absence of N -acetyl cysteine (NAC, 5 mM) and PhosSTOP phosphatase inhibitor (1×); (B) corresponding cytotoxicity in HCT-15 cells under similar treatment conditions. NAC pre-treatment significantly reduces N1-induced cytotoxicity, indicating the involvement of ROS, while PhosSTOP treatment partially attenuates cytotoxicity, suggesting a possible contribution of phosphate-related processes. Data are expressed as mean ± SD ( n = 3; *** p < 0.001, **** p < 0.0001 vs. N1-treated group).

Journal: RSC Advances

Article Title: Exploring an azo-uracil based nickel( ii ) complex for anticancer and phosphatase like activities

doi: 10.1039/d6ra01587e

Figure Lengend Snippet: Effect of ROS scavenging and phosphatase inhibition on N1-induced cytotoxicity: (A) percentage cytotoxicity in CT26 cells treated with N1 (0.04 and 0.08 µg mL −1 ) in the presence or absence of N -acetyl cysteine (NAC, 5 mM) and PhosSTOP phosphatase inhibitor (1×); (B) corresponding cytotoxicity in HCT-15 cells under similar treatment conditions. NAC pre-treatment significantly reduces N1-induced cytotoxicity, indicating the involvement of ROS, while PhosSTOP treatment partially attenuates cytotoxicity, suggesting a possible contribution of phosphate-related processes. Data are expressed as mean ± SD ( n = 3; *** p < 0.001, **** p < 0.0001 vs. N1-treated group).

Article Snippet: Murine colon carcinoma cell lines CT26 and MC-38, human colorectal carcinoma cell line HCT-15, and normal murine fibroblast cell line NIH-3T3 were procured from the ATCC, USA.

Techniques: Inhibition

Recombinant CALR reduces tumor growth and increases M1 macrophages (A) To measure the effect on tumor growth and immune cell activation, bacterial lysate was injected into tumor-bearing mice. Tumors were formed by subcutaneously injecting CT26 murine colon carcinoma cells into the flank of BALB/c mice. After 2 weeks, the mice were injected intratumorally with saline, bacterial control lysate, or lysate from CALR-expressing bacteria. One set of mice received injections at days 0, 3, and 6; were monitored for tumor growth; and their tumors were harvested at day 9 for analysis of immune cells. A second set of mice received only one injection at day 0, and tumors were harvested at day 3 for analysis. (B) Intratumoral injection of CALR lysate decreased tumor growth compared to saline controls ( p = 0.0089). Bacterial control lysate also reduced tumor growth compared to controls ( p = 0.0204). Volumes are reported relative to those on day 0. (C–F) On day 3, recombinant CALR did not affect (C) the number of leukocytes, (D) the number of M1 macrophages (per 10,000 cells analyzed), or the number of M1 macrophages expressing either (E) CD80 or (F) CD86 (per 10,000 cells analyzed) in tumors. (G) On day 9, injection with CALR lysate significantly increased the number of leukocytes in tumors compared to saline controls ( p = 0.0042). (H) On day 9, CALR lysate also significantly increased the number of M1 macrophages in tumors compared to bacterial controls ( p = 0.0480) and saline ( p = 0.0061). (I) CALR lysate significantly increased the number of M1 macrophages expressing CD80 (per 10,000 cells analyzed) compared to saline controls ( p = 0.0063). (J) CALR lysate also increased the number of M1 macrophages expressing CD86 (per 10,000 cells analyzed) compared to bacterial controls ( p = 0.0445) and saline ( p = 0.0077). Data are represented as mean ± SEM. The statistical comparisons in (B) are two-way ANOVA followed by Tukey’s method. The statistical comparisons in (C–J) are ANOVA followed by Tukey’s method. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.

Journal: Molecular Therapy Oncology

Article Title: Recombinant CALR polarizes and activates macrophages in tumors

doi: 10.1016/j.omton.2025.201121

Figure Lengend Snippet: Recombinant CALR reduces tumor growth and increases M1 macrophages (A) To measure the effect on tumor growth and immune cell activation, bacterial lysate was injected into tumor-bearing mice. Tumors were formed by subcutaneously injecting CT26 murine colon carcinoma cells into the flank of BALB/c mice. After 2 weeks, the mice were injected intratumorally with saline, bacterial control lysate, or lysate from CALR-expressing bacteria. One set of mice received injections at days 0, 3, and 6; were monitored for tumor growth; and their tumors were harvested at day 9 for analysis of immune cells. A second set of mice received only one injection at day 0, and tumors were harvested at day 3 for analysis. (B) Intratumoral injection of CALR lysate decreased tumor growth compared to saline controls ( p = 0.0089). Bacterial control lysate also reduced tumor growth compared to controls ( p = 0.0204). Volumes are reported relative to those on day 0. (C–F) On day 3, recombinant CALR did not affect (C) the number of leukocytes, (D) the number of M1 macrophages (per 10,000 cells analyzed), or the number of M1 macrophages expressing either (E) CD80 or (F) CD86 (per 10,000 cells analyzed) in tumors. (G) On day 9, injection with CALR lysate significantly increased the number of leukocytes in tumors compared to saline controls ( p = 0.0042). (H) On day 9, CALR lysate also significantly increased the number of M1 macrophages in tumors compared to bacterial controls ( p = 0.0480) and saline ( p = 0.0061). (I) CALR lysate significantly increased the number of M1 macrophages expressing CD80 (per 10,000 cells analyzed) compared to saline controls ( p = 0.0063). (J) CALR lysate also increased the number of M1 macrophages expressing CD86 (per 10,000 cells analyzed) compared to bacterial controls ( p = 0.0445) and saline ( p = 0.0077). Data are represented as mean ± SEM. The statistical comparisons in (B) are two-way ANOVA followed by Tukey’s method. The statistical comparisons in (C–J) are ANOVA followed by Tukey’s method. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.

Article Snippet: JAWSII murine dendritic cells and CT26 murine colon carcinoma cells were obtained from ATCC, confirmed by STR profiling by Charles River Research Animal Diagnostic Services, and passaged for fewer than 6 months.

Techniques: Recombinant, Activation Assay, Injection, Saline, Control, Expressing, Bacteria

Recombinant CALR increases helper T cell activity in tumors (A) The extent of T cell infiltration was determined in mice (see ) with CT26 tumors that were intratumorally injected (on days 0, 3, and 6) with saline (PBS), bacterial control lysate (BC), or lysate from CALR-expressing bacteria (CALR). On day 9, injection of CALR lysate significantly increased the number of T cells in tumors (per 10,000 cells analyzed) compared to saline controls ( p = 0.0495). (B) The percentage of helper T cells per 10,000 cells analyzed. (C) On day 9, injection with CALR lysate significantly increased the number of activated helper T cells (per 10,000 cells analyzed) in tumors compared to saline controls ( p = 0.0067). Data are represented as mean ± SEM. The statistical comparisons in (A–C) are ANOVA followed by Dunnett’s test. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.

Journal: Molecular Therapy Oncology

Article Title: Recombinant CALR polarizes and activates macrophages in tumors

doi: 10.1016/j.omton.2025.201121

Figure Lengend Snippet: Recombinant CALR increases helper T cell activity in tumors (A) The extent of T cell infiltration was determined in mice (see ) with CT26 tumors that were intratumorally injected (on days 0, 3, and 6) with saline (PBS), bacterial control lysate (BC), or lysate from CALR-expressing bacteria (CALR). On day 9, injection of CALR lysate significantly increased the number of T cells in tumors (per 10,000 cells analyzed) compared to saline controls ( p = 0.0495). (B) The percentage of helper T cells per 10,000 cells analyzed. (C) On day 9, injection with CALR lysate significantly increased the number of activated helper T cells (per 10,000 cells analyzed) in tumors compared to saline controls ( p = 0.0067). Data are represented as mean ± SEM. The statistical comparisons in (A–C) are ANOVA followed by Dunnett’s test. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.

Techniques: Recombinant, Activity Assay, Injection, Saline, Control, Expressing, Bacteria

Review

Structured Review

Images

1) Product Images from "Lung-targeted cytokine-coding RNA-lipoplexes induce T and NK cell-mediated anti-tumor immune response"

Similar Products

Image Search Results